News - Dainippon Sumitomo Pharma, Neurological

Filter

Popular Filters

Dainippon Sumitomo and Daiichi Sankyo cooperate on lurasidone in South America

Dainippon Sumitomo and Daiichi Sankyo cooperate on lurasidone in South America

28-05-2014

Japanese drug majors Dainippon Sumitomo Pharma and Daiichi Sankyo have entered into a license agreement…

ArgentinaBrazilDaiichi SankyoDainippon Sumitomo PharmaLicensinglurasidoneNeurologicalPharmaceuticalSouth AmericaVenezuela

US FDA calls for lower starting dose for sleep drug Lunesta

16-05-2014

The US Food and Drug Administration says it has required the manufacturer of the sleep drug Lunesta (eszopiclone)…

Dainippon Sumitomo PharmaLunestaNeurologicalPharmaceuticalRegulationSunovion PharmaceuticalsUSA

Teva and Dr Reddy’s latest to launch generic Lunesta in USA

16-04-2014

Two more companies have debuted generic versions of the insomnia drug Lunesta (eszopiclone) tablets,…

Dainippon Sumitomo PharmaDr Reddy's LaboratoriesGenericsLunestaMarkets & MarketingNeurologicalNorth AmericaSunovion PharmaceuticalsTeva Pharmaceutical IndustriesUSA

Sunovion’s once-daily epilepsy drug Aptiom debuts in USA

08-04-2014

USA-based Sunovion Pharmaceuticals, a subsidiary of Japanese drug major Dainippon Sumitomo, has launched…

AptiomDainippon Sumitomo PharmaMarkets & MarketingNeurologicalNorth AmericaPharmaceuticalSunovionUSA

EU approval for Dainippon Sumitomo and Takeda’s Latuda

EU approval for Dainippon Sumitomo and Takeda’s Latuda

28-03-2014

Japanese drug majors Dainippon Sumitomo Pharma and Takeda Pharmaceutical have received European Commission…

Dainippon Sumitomo PharmaEuropeLatudaNeurologicalPharmaceuticalRegulationSunovionTakeda Pharmaceuticals

Edison Pharma in deal with Dainippon Sumitomo potentially worth $4.3 billion

Edison Pharma in deal with Dainippon Sumitomo potentially worth $4.3 billion

31-01-2014

Privately-held US company Edison Pharmaceuticals has entered into a new strategic alliance valued up…

Dainippon Sumitomo PharmaEdison PharmaceuticalsEPI-589LicensingMetabolicsNeurologicalPharmaceutical

FDA thumbs up for Sunovion’s Aptiom as once-daily adjunctive for partial-onset seizures

FDA thumbs up for Sunovion’s Aptiom as once-daily adjunctive for partial-onset seizures

09-11-2013

The US Food and Drug Administration on Friday approved Sunovion Pharmaceutical’s (a subsidiary of Japanese…

AptiomDainippon Sumitomo PharmaNeurologicalNorth AmericaPharmaceuticalRegulationSunovion

Report: Latuda has greatest commercial potential among new agents entering the bipolar drug market

Report: Latuda has greatest commercial potential among new agents entering the bipolar drug market

15-10-2013

Dainippon Sumitomo Pharma/Sunovion/Takeda Pharmaceutical’s atypical antipsychotic Latuda (lurasidone)…

Dainippon Sumitomo PharmaGlobalLatudaMarkets & MarketingNeurologicalPharmaceuticalTakeda Pharmaceuticals

Sunovion's eslicarbazepine successful in Ph III epilepsy studies

18-09-2013

Sunovion Pharmaceuticals, a US subsidiary of Japan's Dainippon Sumitomo Pharma (TYO: 4506), says that…

Dainippon Sumitomo PharmaeslicarbazepineNeurologicalPharmaceuticalResearchSunovion

Takeda gains first European approval for lurasidone

14-08-2013

Japan's largest drugmaker Takeda Pharma (TYO: 4502) says it has been granted approval by Switzerland's…

Dainippon Sumitomo PharmaEuropeLatudalurasidoneNeurologicalPharmaceuticalRegulationTakeda Pharmaceuticals

Sunovion announces novel drug discovery partnership

14-08-2013

Sunovion Pharmaceuticals, a wholly-owned US subsidiary of Japanese drug major Dainippon Sumitomo Pharma…

AfraxisDainippon Sumitomo PharmaLicensingNeurologicalPharmaceuticalResearchSunovion

US FDA backs news indications for Latuda; grants Priority Review for Perjeta

02-07-2013

Sunovion Pharmaceuticals, a US subsidiary of Japan's Dainippon Sumitomo Pharma (TYO: 4506), says that…

BiotechnologyDainippon Sumitomo PharmaLatudaNeurologicalNorth AmericaOncologyPerjetaPharmaceuticalRegulationRocheSunovion

Dainippon Sumitomo gains rights to Edison Pharma drug candidates in up to $545 million accord

02-04-2013

Privately-held US firm Edison Pharmaceuticals has entered into a research, development and commercialization…

Dainippon Sumitomo PharmaEdison PharmaceuticalsEPI-589EPI-743LicensingNeurologicalPharmaceuticalResearch

Sunovion files two sNDAs for Latuda with FDA

09-09-2012

Sunovion Pharmaceuticals, a US subsidiary of Japanese drug major Dainippon Sumitomo (TYO: 4506) has submitted…

Dainippon Sumitomo PharmaLatudaNeurologicalNorth AmericaPharmaceuticalRegulationSunovion

US patent settlements of Xopenex and Lidoderm

30-05-2012

US generics drug major Mylan (Nasdaq: MYL) has entered into a settlement agreement with Sunovion Pharmaceuticals,…

Dainippon Sumitomo PharmaEndo PharmaceuticalsGenericsLidodermMylan LaboratoriesNeurologicalNorth AmericaPatentsRespiratory and PulmonarySunovionWatson PharmaceuticalsXopenex

Dainippon Sumitomo's Latuda meets key endpoints in two Ph III trials in bipolar I depression

09-05-2012

Japanese drugmaker Dainippon Sumitomo Pharma (4506: JP) Co., Ltd. (DSP) announced has results from two…

Dainippon Sumitomo PharmaLatudaNeurologicalPharmaceuticalResearch

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top